PellePharm Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 18
Employees
  • Latest Deal Type
  • Corporate
  • Latest Deal Amount
  • $70M
Latest Deal Amount
  • Investors
  • 7

PellePharm General Information

Description

Developer of skin cancer therapeutics designed to mitigate the tumor burden with basal cell carcinomas. The company's therapeutics include topical hedgehog inhibitor which decreases the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Primary Office
  • 101 Mission Street
  • Suite 1950
  • San Francisco, CA 94105
  • United States

PellePharm Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PellePharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Corporate 20-Nov-2018 $70M 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 18-Jun-2018 00.00 000.00 00000 Completed Generating Revenue
4. Debt - General 29-Mar-2018 00.00 000.00 Completed Generating Revenue
3. Early Stage VC (Series B2) 31-Jul-2017 0000 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series B) 23-Jul-2015 $4.55M $7.67M 000.00 Completed Startup
1. Early Stage VC (Series A) 11-May-2015 $3.12M $3.12M 00.00 Completed Startup
To view PellePharm’s complete valuation and funding history, request access »

PellePharm Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series B2 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 3,888,889 $0.000100 $0.09 $1.17 $1.17 1x $1.17 8.67%
Series A 3,712,649 $0.000100 $0.84 $0.84 1x $0.84 8.27%
To view PellePharm’s complete cap table history, request access »

PellePharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of skin cancer therapeutics designed to mitigate the tumor burden with basal cell carcinomas. The company's th
Drug Discovery
San Francisco, CA
18 As of 2020
00000
000000000000 00000

00000000

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000000000000
000.00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PellePharm Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000000 000000000 Corporate Backed or Acquired 000.00 000000&0
To view PellePharm’s complete competitors history, request access »

PellePharm Executive Team (7)

Name Title Board Seat Contact Info
Sanuj Ravindran MD Chief Executive Officer, President & Board Member
Sharon Kokubun Vice President of Finance & Controller
Ervin Epstein MD Co-Founder, Medical Advisor & Board Member
Jean Tang MD Co-Founder, Board Member & Medical Advisor
Philip Beachy Ph.D Co-Founder
You’re viewing 5 of 7 executive team members. Get the full list »

PellePharm Board Members (7)

Name Representing Role Since
Anders Kronborg Self Board Member 000 0000
Eric Aguiar MD Aisling Capital Board Observer 000 0000
Frank McCormick Ph.D Self Board Member 000 0000
Jean Tang MD PellePharm Co-Founder, Board Member & Medical Advisor 000 0000
Katrin Andreasson PellePharm Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

PellePharm Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PellePharm Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
LEO Pharma Corporation Minority 000 0000 000000 0
Aisling Capital Venture Capital Minority 000 0000 000000 0
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
BridgeBio Corporation Minority 000 0000 000000 0
The Atlanta Trust Other Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »